UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the quarterly period ended MARCH 31, 2000
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from ________________________ to _____________________
Commission file number: 0-22052
PROXYMED, INC.
--------------
(Exact name of registrant as specified in its charter)
FLORIDA 65-0202059
------- ----------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
2555 DAVIE ROAD, SUITE 110, FT. LAUDERDALE, FLORIDA 33317
- -----------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(954) 473-1001
--------------
(Registrant's telephone number)
-------------------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. [X] Yes [ ] No
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date:
COMMON STOCK, $.001 PAR VALUE
19,734,429 SHARES AS OF MAY 8, 2000
<PAGE>
PART 1 - FINANCIAL INFORMATION
ITEM 1 - FINANCIAL STATEMENTS.
PROXYMED, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
<TABLE>
<CAPTION>
PRO FORMA
MARCH 31, MARCH 31, DECEMBER 31,
2000 2000 1999
------------- ------------- -------------
<S> <C> <C> <C>
Current assets:
Cash and cash equivalents $ 7,914,054 $ 7,914,054 $ 11,487,938
Accounts receivable - trade, net 3,855,808 3,855,808 3,298,298
Notes and other receivables 1,896,972 1,896,972 246,366
Inventory 2,442,994 2,442,994 1,842,055
Other current assets 615,030 615,030 419,410
Net current assets of discontinued operations -- -- 1,719,791
------------- ------------- -------------
Total current assets 16,724,858 16,724,858 19,013,858
Property and equipment, net 4,752,195 4,752,195 4,321,943
Goodwill, net 7,997,782 7,997,782 9,629,115
Purchased technology, capitalized software and other intangibles, net 9,840,510 9,840,510 10,027,887
Other assets 482,600 482,600 477,742
Net long-term assets of discontinued operations -- -- 1,302,339
------------- ------------- -------------
Total assets $ 39,797,945 $ 39,797,945 $ 44,772,884
============= ============= =============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Note payable $ 1,000,000 $ 1,000,000 $ 1,000,000
Current portion of long-term debt 750,000 750,000 735,788
Accounts payable and accrued expenses 6,329,640 6,329,640 4,263,032
Deferred revenue 628,674 628,674 435,349
------------- ------------- -------------
Total current liabilities 8,708,314 8,708,314 6,434,169
Long-term deferred revenue and other long-term liabilities 527,027 527,027 583,136
------------- ------------- -------------
Total liabilities 9,235,341 9,235,341 7,017,305
------------- ------------- -------------
Series B 6% Convertible preferred stock 15,145,000 -- --
Stockholders' equity:
Series B 6% Convertible preferred stock - $.01 par value
Authorized, issued and outstanding 15,000 shares;
liquidation preference $16,050,000 20 150 150
Common stock - $.001 par value. Authorized 50,000,000 shares;
issued and outstanding 18,299,205 (after deducting 225,913
shares in treasury) and 18,327,402 shares, respectively 18,299 18,299 18,327
Additional paid-in capital 84,861,713 100,006,583 101,477,438
Accumulated deficit (69,462,428) (69,462,428) (63,740,336)
------------- ------------- -------------
Total stockholders' equity 15,417,604 30,562,604 37,755,579
------------- ------------- -------------
Total liabilities and stockholders' equity $ 39,797,945 $ 39,797,945 $ 44,772,884
============= ============= =============
</TABLE>
See accompanying notes.
2
<PAGE>
PROXYMED, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31,
------------------------------
2000 1999
------------ ------------
<S> <C> <C>
Revenues:
Services and license fees $ 4,254,348 $ 4,486,981
Communication devices, computer systems
and other tangible goods 3,390,602 3,038,078
------------ ------------
7,644,950 7,525,059
------------ ------------
Costs and expenses:
Cost of services and license fees 405,392 256,871
Cost of tangible goods 2,339,490 1,877,958
Selling, general and administrative expenses 7,639,385 6,056,803
Depreciation and amortization 3,283,209 3,156,295
------------ ------------
13,667,476 11,347,927
------------ ------------
Operating loss (6,022,526) (3,822,868)
Interest income, net 93,231 18,780
------------ ------------
Loss from continuing operations (5,929,295) (3,804,088)
Discontinued operations:
Income (loss) from discontinued operations (303,927) 113,682
Gain on disposal of discontinued operations 511,130 --
------------ ------------
207,203 113,682
------------ ------------
Net loss (5,722,092) (3,690,406)
Dividends on cumulative preferred stock 223,770 --
------------ ------------
Net loss applicable to common shareholders $ (5,945,862) $ (3,690,406)
============ ============
Weighted average common shares outstanding 18,434,539 17,818,894
============ ============
Basic and diluted net income (loss) per share of common stock:
From continuing operations $ (.33) $ (.22)
From discontinued operations .01 .01
------------ ------------
Net loss $ (.32) $ (.21)
============ ============
</TABLE>
See accompanying notes.
3
<PAGE>
PROXYMED, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31,
------------------------------
2000 1999
------------ ------------
<S> <C> <C>
Cash flows from operating activities:
Net loss $ (5,722,092) $ (3,690,406)
Adjustments to reconcile net loss to net cash provided by
(used in) operating activities:
Depreciation and amortization 3,613,883 3,268,896
Provision for doubtful accounts 87,868 73,091
Compensatory stock options issued 10,000 --
Net gain on sales of discontinued operations (511,130) --
Changes in net current assets of discontinued operations (734,577) 421,816
Changes in assets and liabilities, net of
effect of acquisitions and dispositions:
Accounts and other receivables (582,494) (298,924)
Inventory (600,939) 91,228
Prepaid expenses (195,013) (43,030)
Accounts payable and accrued expenses 2,513,846 52,470
Deferred revenue 143,325 221,110
Other, net (12,730) (89,704)
------------ ------------
Net cash provided by (used in) operating activities (1,990,053) 6,547
------------ ------------
Cash flows from investing activities:
Capital expenditures (752,449) (220,271)
Capital expenditures of discontinued operations (230,072) (93,652)
Capitalized software (1,017,302) (150,000)
Acquisition of business, net of cash acquired -- (1,000,000)
Payments for acquisition-related costs (5,199) (314,178)
------------ ------------
Net cash used in investing activities (2,005,022) (1,778,101)
------------ ------------
Cash flows from financing activities:
Proceeds from exercise of stock options and warrants 426,749 52,252
Payment of notes payable (5,558) (7,799)
------------ ------------
Net cash provided by financing activities 421,191 44,453
------------ ------------
Net decrease in cash (3,573,884) (1,727,101)
Cash and cash equivalents at beginning of period 11,487,938 4,626,649
------------ ------------
Cash and cash equivalents at end of period $ 7,914,054 $ 2,899,548
============ ============
</TABLE>
See accompanying notes.
4
<PAGE>
PROXYMED, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(a) BASIS OF PRESENTATION - The accompanying unaudited condensed
consolidated financial statements of ProxyMed, Inc. and subsidiaries
(the "Company") have been prepared in accordance with the instructions
to Form 10-Q and do not include all of the information and disclosures
required by generally accepted accounting principles. However, such
information reflects all adjustments (consisting solely of normal
recurring adjustments) which are, in the opinion of management,
necessary for a fair statement of results for the interim periods.
The results of operations for the three months ended March 31, 2000 are
not necessarily indicative of the results to be expected for the full
year. The unaudited consolidated financial statements included herein
should be read in conjunction with the audited consolidated financial
statements and the notes thereto included in the Company's Form 10-K
for the year ended December 31, 1999.
On March 31, 2000, ProxyMed sold its non-core network integration and
prescription drug dispensing segments. These two segments are shown as
discontinued operations and the consolidated financial statements and
related notes have been reclassified to segregate the net assets and
operating results of these segments (see Note 2). Certain prior period
amounts have been reclassified to conform to the current period
presentation.
(b) REVENUE RECOGNITION - Electronic transaction processing fee revenue is
recorded in the period the service is rendered. Revenue from sales of
software, software licenses, computer hardware and manufactured goods
is recognized when persuasive evidence of an arrangement exists,
delivery has occurred, the price is fixed or determinable and
collectibility is probable. The same criteria is applied to each
element of multiple element arrangements after allocating the amounts
paid to individual elements based on vendor-specific objective evidence
of fair value. Revenue from hardware leases, software rentals and
maintenance fees is recognized ratably over the applicable period.
(c) NET LOSS PER SHARE - Basic loss per share of common stock is computed
by dividing net loss applicable to common shareholders by the weighted
average shares of common stock outstanding during the year. Diluted per
share results reflect the potential dilution from the exercise or
conversion of securities into common stock; however, stock options,
warrants and contingent shares totaling 4,290,978 shares and 2,777,455
shares at March 31, 2000 and 1999, respectively, as well as common
shares issuable on conversion of preferred stock (1,897,533 shares, if
converted on March 31, 2000) were excluded from the calculation of
diluted per share results because their effect was antidilutive. If the
preferred stock had been converted to common stock as of the beginning
of 2000, net loss per share from
5
<PAGE>
continuing operations would have been $(.30) and total net loss per
share would have been $(.29) for the three months ended March 31, 2000.
(2) DISCONTINUED OPERATIONS - In March 2000, ProxyMed sold its discontinued
network integration and prescription drug dispensing segments in separate
transactions. Proceeds from the sale of the network integration segment
were $3,398,000 and were paid with 208,913 shares of ProxyMed common stock
(valued at $1,776,000, the closing market price of the common stock on the
date of closing, and recorded as treasury stock) and a note receivable of
$1,622,000 due on July 31, 2000. The sale resulted in a gain of $574,000.
Proceeds from the sale of the prescription drug dispensing segment were
$255,000 and were paid with 17,000 shares of ProxyMed common stock (valued
at $154,000, the closing market price of the common stock on the date of
closing, and recorded as treasury stock) and a note receivable of $101,000
payable in monthly installments over two years and bearing interest at 9%
per annum. The sale resulted in a loss of $63,000.
The following table represents the results of discontinued operations for
the three months ended March 31, 2000 and 1999:
<TABLE>
2000 1999
----------- -----------
<S> <C> <C>
Net revenues:
Network integration $ 2,371,758 $ 3,354,923
Prescription drug dispensing 574,665 487,327
----------- -----------
$ 2,946,423 $ 3,842,250
=========== ===========
Net income (loss):
Network integration $ (327,767) $ 135,528
Prescription drug dispensing 23,840 (21,846)
----------- -----------
$ (303,927) $ 113,682
=========== ===========
</TABLE>
6
<PAGE>
(3) SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31,
----------------------------
2000 1999
----------- -----------
<S> <C> <C>
Common stock issued for payment of preferred stock dividends $ 223,770 $ --
=========== ===========
Acquisition of business:
Common stock and warrants issued for business acquired $ -- $ 181,563
Other acquisition costs accrued -- 174,000
Details of acquisition:
Working capital components, other than cash -- (206,408)
Property and equipment -- (38,546)
Goodwill -- (999,549)
Other intangible assets -- (111,060)
----------- -----------
Net cash used in acquisitions $ -- $(1,000,000)
=========== ===========
Disposition of businesses:
Common stock received $(1,929,823) $ --
Notes and other receivables received (1,723,125) --
Net gain recognized 511,130
Details of dispositions:
Working capital components, other than cash 1,940,081 --
Property and equipment 1,070,926 --
Goodwill 109,658 --
Other assets 21,153 --
----------- -----------
Net cash provided by dispositions $ -- $ --
=========== ===========
</TABLE>
(4) RELATED PARTY TRANSACTION
In April 1997, the Company loaned a total of $350,000 to ProxyMed's
chairman of the board. The funds were advanced pursuant to two demand
promissory notes in the principal amounts of $290,000 and $60,000,
respectively, each bearing interest at a rate of 7-3/4% per annum. The
chairman and the Company's Compensation Committee are in current
discussions with respect to the repayment terms and collateral for such
notes.
(5) SUBSEQUENT EVENT
On December 23, 1999, the Company issued 15,000 shares of its Series B
Preferred Stock, par value $.01 per share (the "Series B Preferred") and
warrants to purchase 800,000 shares (the "Old Warrants") of its common
stock, par value $.001 per share, in a private placement to institutional
investors.
Due to the decline in the price of the Company's common stock below $4.21
for a period of ten consecutive trading days in April and May 2000, certain
contractual
7
<PAGE>
effects were triggered which would permit the preferred shareholders to
convert the preferred shares and exercise the Old Warrants into a
potentially large number of shares of common stock. To mitigate the
potential dilution to existing shareholders, on May 4, 2000, the Company
entered into a Redemption and Exchange Agreement (the "Redemption
Agreement") with holders of 13,000 shares of the Series B Preferred. Under
the terms of the Redemption Agreement, the Company redeemed 4,000 shares of
the Series B Preferred, and is required to redeem an additional 2,500
shares of the Series B Preferred on each of June 19, 2000, August 1, 2000,
and August 31, 2000, and an additional 1,500 shares of the Series B
Preferred on September 29, 2000. The Redemption Agreement provides that the
redemption of the Series B Preferred will be made at 116.5% of the
Conversion Amount (as defined in the Articles of Amendment to the Company's
Articles of Incorporation creating the Series B Preferred, the "Articles of
Amendment") of such Series B Preferred on the date of such redemption. The
Redemption Agreement also provides that 693,333 of the Old Warrants with an
exercise price of $12.05 per share issued to the holders of the Series B
Preferred subject to the Redemption Agreement have been exchanged for an
equal number of warrants (the "Exchanged Warrants") with an exercise price
of $1.50 per share. Such holders also received, in the aggregate, 650,000
additional warrants (the "New Warrants") at an exercise price of $1.50 per
share. The Exchanged Warrants expire on December 23, 2002 and the New
Warrants expire on May 5, 2003. The exercise price and number of shares of
common stock which may be purchased upon exercise of the Exchanged Warrants
and the New Warrants are subject to adjustment upon the occurrence of
certain dilution events including, without limitation, certain issuances of
common stock, stock options or convertible securities issued after November
2000, or certain corporate transactions such as stock splits, mergers or
asset sales. Subject to certain restrictions, the holders of the Exchanged
Warrants and the New Warrants have agreed not to exercise such warrants for
a period of 180 days following their date of issuance. The redemption of
the Series B Preferred in accordance with the Redemption Agreement is
subject to certain closing conditions on each date of redemption. So long
as the Company remains in compliance with the terms of the Redemption
Agreement, such holders are prohibited from converting their shares of
Series B Preferred into shares of common stock.
Under the terms of the Redemption Agreement, the Company has agreed to pay
the holders of Series B Preferred subject to such agreement the aggregate
amount of $4,333,333 if there is a change of control of the Company on or
before December 23, 2002.
The Company has not entered into an agreement to redeem the shares of
Series B Preferred held by the holder of 2,000 shares of the Series B
Preferred. To date, this holder has converted 1,690 shares of the Series B
Preferred into an aggregate of 1,401,516 shares of common stock, and 310
shares of Series B Preferred remain outstanding. In addition, as a result
of certain anti-dilution provisions, 106,667 warrants originally issued at
an exercise price of $12.05 have been reset in both number and price so
that there are presently 856,892 warrants at an exercise price of $1.50.
8
<PAGE>
In order for the Company to comply with the terms of the Redemption
Agreement and continue to fund its operating requirements, it will be
required to raise significant amounts of additional capital. The Redemption
Agreement provides that the Company must raise at least $4,000,000 of
additional funds by June 17, 2000, an additional $5,000,000 of new funds by
July 31, 2000, and an additional $4,000,000 of new funds by August 30,
2000. As a result of these redemptions, the Company will report a
substantial charge in the second quarter of 2000. The Company, however, may
need or elect to raise additional funds in excess of such amounts prior to
or after such dates. The Company's capital requirements will depend on many
factors, including its ability to meet the conditions under the Redemption
Agreement, the problems, delays, expenses and complications frequently
encountered by other eHealth companies; the costs associated with
developing improved products and services in response to technological
changes; the costs associated with any marketing or other arrangements;
changes in economic, regulatory, or competitive conditions or the Company's
business; and the cost of retaining management personnel. As a result of
the foregoing, the pro forma capitalization is reflected in the
consolidated balance sheet as of March 31, 2000.
To satisfy its capital requirements, the Company must raise funds through
the issuance of equity or debt in the public or private capital markets.
The Company's ability to raise additional funds may be adversely affected
if, among other things, it is unable to meet the terms and conditions set
forth in the Redemption Agreement or if it does not continue to improve its
operating performance and achieve increased market acceptance of its
products and services. There can be no assurance that any additional
funding will be available to the Company, or if available, that it will be
available on acceptable terms. If adequate funds are not available, the
Company will not be able to meet the conditions set forth in the Redemption
Agreement and the holders of the Series B Preferred would be entitled to
exercise their conversion and other rights under the terms of the
designations for the Series B Preferred and the Redemption Agreement. If
the Company is successful in obtaining additional financing, the terms of
the financing may have the effect of significantly diluting or adversely
affecting the holdings or the rights of the holders of common stock.
On May 8, 2000, the Company entered into an agreement with an investment
bank to serve as exclusive placement agent for the Company in connection
with a proposed private offering by the investment bank, on a best efforts
basis, of up to $20,000,000 of equity securities, plus an "overallotment
option" for an additional $10,000,000. In addition, at the option of both
parties, the investment bank may arrange for up to $6,000,000 of bridge
financing for the Company in the form of an 8% senior collateralized
convertible promissory note and five year warrants to purchase 500,000
shares of common stock for each $1,000,000 of bridge financing. No
assurance can be given that these financings will be completed, or that, if
completed, will be at the terms described herein.
9
<PAGE>
ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
GENERAL
ProxyMed is an eHealth company providing eSolutions to physicians and
business-to-business healthcare electronic commerce services to healthcare
information system suppliers such as pharmacies, commercial and hospital
laboratories, insurance companies, managed care organizations and nursing homes.
Our products and services are provided from our three operating facilities
located in Fort Lauderdale, Florida; Santa Ana, California; and New Albany,
Indiana.
In May 1999, we announced and commenced the development of
PROXYMED.COM, a healthcare portal website aimed at increasing the use of our
services through the internet and in November 1999, the first version of the
website was introduced. In March 2000, Version 2.0 of the portal was introduced
with our first three transaction services: eligibility verification, laboratory
test results reporting, and drug formulary management. When fully developed,
PROXYMED.COM will offer a secure, single access point through the web for all
connectivity needs of physicians and other healthcare providers to facilitate
healthcare eCommerce services.
In March 2000, we sold our non-core network integration and
prescription drug dispensing segments. These two segments are shown as
discontinued operations in the consolidated financial statements.
RESULTS OF OPERATIONS
THREE MONTHS ENDED MARCH 31, 2000 COMPARED TO THREE MONTHS ENDED MARCH 31, 1999
NET REVENUES. Consolidated net revenues for the three months ended
March 31, 2000 increased by $119,891, or 2%, to $7,644,950 from consolidated net
revenues of $7,525,059 for the three months ended March 31, 1999. This increase
is primarily due to volume increases in transactions processed.
COST OF SALES AND GROSS PROFIT MARGIN. Cost of services and license
fees includes third-party electronic transaction processing costs, certain
telecommunication costs, third-party databases, and certain labor and travel
costs. Cost of sales for communication devices, computer systems, and other
tangible goods includes hardware, third-party software, direct labor and
consumable materials. Consolidated gross profit margin for the three months
ended March 31, 2000 was 64% compared to 72% for the three months ended March
31, 1999. This decrease was primarily due to a change in the mix of revenues at
our laboratory communication device operations from higher margin leasing of
communication devices to lower margin sales and servicing of these devices.
10
<PAGE>
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES. Consolidated selling,
general and administrative expenses for the three months ended March 31, 2000
increased by $1,582,582, or 26%, to $7,639,385 from consolidated SG&A expenses
of $6,056,803 for the three months ended March 31, 1999. This increase is
primarily due to (i) increases in payroll and related expenses for additional
sales representatives, field implementation and senior management positions
($886,000), (ii) increases in selling and marketing expenses for our current
products and PROXYMED.COM ($384,000), (iii) increases in telecommunications and
facilities costs for additional employees ($148,000), and (iv) increases in
professional fees for legal and consulting projects ($166,000). As a result of
these factors, consolidated SG&A expenses as a percentage of consolidated net
sales increased to 100% in the 2000 period from 80% in the 1999 period.
DEPRECIATION AND AMORTIZATION. Consolidated depreciation and
amortization expense increased $126,914, or 4%, to $3,283,209 for the three
months ended March 31, 2000 from $3,156,295 for the three months ended March 31,
1999. This increase was primarily due to additional fixed assets purchased for
our computer networks and additional employees.
LOSS FROM CONTINUING OPERATIONS. As a result of the foregoing, the loss
from continuing operations was $6,022,526 for the three months ended March 31,
2000 compared to a loss from continuing operations of $3,822,868 for the three
months ended March 31, 1999.
DISCONTINUED OPERATIONS. As a result of selling both the network
integration and prescription drug dispensing segments in the first quarter of
2000 for total proceeds of $3,652,942, we recorded a net gain of $511,130. The
loss from the operations of our discontinued network integration and
prescription drug dispensing segments was $303,927 in the three months ended
March 31, 2000 compared to income of $113,682 in the three months ended March
31, 1999.
Revenues from the network integration segment were $2,371,758 in the
three months ended March 31, 2000 compared to $3,354,923 in the three months
ended March 31, 1999. As a result of the decreased sales and additional
amortization expense related to goodwill, the net loss for this segment was
$327,767 in the 2000 period compared to net income of $135,528 in the 1999
period.
Revenues from the prescription drug dispensing segment were $574,665
for the three months ended March 31, 2000 compared to $487,327 for in the three
months ended March 31, 1999. Net income for this segment was $23,840 in the 2000
period compared to a net loss of $21,846 in the 1999 period.
DIVIDENDS. As a result of the issuance of preferred stock in December
1999, we paid dividends of $223,770 by issuing 29,278 shares of our common stock
on March 31, 2000.
11
<PAGE>
NET LOSS APPLICABLE TO COMMON SHAREHOLDERS. As a result of the
foregoing, we recorded a net loss applicable to common shareholders of
$5,945,862 for the three months ended March 31, 2000 compared to $3,690,406 for
the three months ended March 31, 1999.
LIQUIDITY AND CAPITAL RESOURCES
In the three month period ended March 31, 2000, cash used in operating
activities totaled $1,990,053. This was primarily due to our net loss partially
offset by depreciation and amortization charges. We spent approximately
$2,000,000 for fixed assets and capitalized software development costs, and paid
dividends to our preferred stockholders with 29,278 shares of common stock.
These activities were financed through available cash resources and $426,749 in
proceeds from the exercise of stock options and warrants. After these
expenditures and sales of equity, we had cash and cash equivalents totaling
$7,914,054 as of March 31, 2000.
These available funds continue to be used for operations, the further
development and marketing of our products and services (including PROXYMED.COM,
our healthcare portal website), equipment and other general corporate purposes.
As a result of the completed sales of our network integration and prescription
drug dispensing segments in March 2000, we will receive payments of
approximately $1,658,000 through July 2000. Additionally, as a result of
acquisitions made in 1997 and 1998, we are obligated to pay approximately
$330,000 for a final assessment of a tax audit at Key Communications (which was
paid in April 2000), $750,000 to the former owner of Clinical Microsystems
(which was paid in April 2000 for $375,000 in cash and 33,708 shares of common
stock), and $500,000 in June 2000 to the former owner of PreScribe. In addition,
we are continuously evaluating acquisition opportunities and other strategic
alternatives that may add synergies to our product offerings and business
strategy.
We are aggressively implementing our new strategic plan which
concentrates on empowering physicians with internet-enabled tools and solutions
in three critical areas: (i) accelerating the development and launch of
PROXYMED.COM and clinical applications, (ii) aggressively adding physician-users
to our desktop software, and (iii) enhancing our suppliers network to deliver
additional physician customers and new physician services. We continue to expect
that there will be opportunities to increase revenues by cross-selling products
and services to our current customers utilizing only selected services, as well
as revenue opportunities from the development of new services from our product
development efforts, including PROXYMED.COM. In addition, while we expect
certain sales, marketing, implementation and development costs to rise in order
to achieve our revenue goals, we also expect to continue to experience cost
reduction synergies as we utilize the operational strengths at each of our
locations. These savings will occur primarily from elimination of facilities,
duplicate personnel in the areas of network operations, management and customer
service, and other general and administrative costs.
In December 1999, we issued 15,000 shares of Series B Preferred Stock,
par value $.01 per share (the "Series B Preferred") and warrants to purchase
800,000 shares (the
12
<PAGE>
"Old Warrants") of our common stock, par value $.001 per share, in a private
placement to institutional investors. Due to the decline in the price of the our
common stock below $4.21 for a period of ten consecutive trading days in April
and May 2000, certain contractual effects were triggered which would permit the
preferred shareholders to convert the preferred shares and exercise the Old
Warrants into a potentially large number of shares of common stock. To mitigate
the potential dilution to existing shareholders, on May 4, 2000, we entered into
a Redemption and Exchange Agreement (the "Redemption Agreement") with holders of
13,000 shares of the Series B Preferred. Under the terms of the Redemption
Agreement, we redeemed 4,000 shares of the Series B Preferred, and are required
to redeem an additional 2,500 shares of the Series B Preferred on each of June
19, 2000, August 1, 2000, and August 31, 2000, and an additional 1,500 shares of
the Series B Preferred on September 29, 2000, plus a 16.5% premium and accrued
dividends.
In order for us to comply with the terms of the Redemption Agreement
and continue to fund our operating requirements, we will be required to raise
significant amounts of additional capital. The Redemption Agreement provides
that we must raise at least $4,000,000 of additional funds by June 17, 2000, an
additional $5,000,000 of new funds by July 31, 2000, and an additional
$4,000,000 of new funds by August 30, 2000. As a result of these redemptions, we
will report a substantial charge in the second quarter of 2000. We, however, may
need or elect to raise additional funds in excess of such amounts prior to or
after such dates. Our capital requirements will depend on many factors,
including our ability to meet the conditions under the Redemption Agreement, the
problems, delays, expenses and complications frequently encountered by other
eHealth companies; the costs associated with developing improved products and
services in response to technological changes; the costs associated with any
marketing or other arrangements; changes in economic, regulatory, or competitive
conditions or our business; and the cost of retaining management personnel.
In July 1999, we signed an accounts receivable-based revolving line of
credit agreement of up to $5,000,000. Borrowings are based on 85% of eligible
accounts receivable, repayable on July 30, 2000, collateralized by a lien on all
of our assets, and bear interest at the prime rate plus 2% payable monthly
(which has ranged from 10% to 11%). If the creditor does not elect to renew this
line of credit, we may need to enter into another credit facility with terms
that may differ significantly from the existing agreement, or raise funds
through additional debt or equity financing. As of March 31, 2000, we borrowed
$1,000,000 under this credit facility and in May 2000, we borrowed an additional
$2,000,000. Our current availability to borrow under this credit facility is
approximately $258,000.
At the current time, we do not have any material commitments for
capital expenditures. To satisfy our capital requirements, we must raise funds
through the issuance of equity or debt in the public or private capital markets.
Our ability to raise additional funds may be adversely affected if, among other
things, we are unable to meet the terms and conditions set forth in the
Redemption Agreement or if we do not continue to improve our operating
performance and achieve increased market acceptance of our products and
services. There can be no assurance that any additional funding will be
available to us, or if available, that it will be available on acceptable terms.
If adequate funds are not available, we will not be able to meet the conditions
set forth in the Redemption Agreement and the holders of the Series B preferred
stock would be entitled to exercise their conversion and other rights under the
terms of the designations for the Series B preferred stock and the Redemption
Agreement. If we are successful in obtaining additional financing, the terms of
the financing may have the effect of significantly diluting or adversely
affecting the holdings or the rights of the holders of our common stock. We
believe that if we are not successful in obtaining additional financing to fund
the increased research and development expenditures, increased marketing
expenditures, and comply with the terms of the Redemption Agreement either
through equity raises or debt issuance, such increased expenditures could be
reduced, and we could operate at near cash flow break-even until such additional
financing is available. However, such actions could impact our ability to
successfully advance our business plan and may put us at a competitive
disadvantage.
The ratio of current assets to current liabilities was 1.9 times at
March 31, 2000 and 3.0 times at December 31, 1999. This decrease is primarily
due to a decrease in cash for operational purposes and increases in liabilities
for payroll and related expenses and higher inventory levels. For the periods
ended March 31, 2000 and 1999, accounts receivable turnover for us was 7.5 times
in the 2000 period and is comparable to 7.6 times
13
<PAGE>
in the 1999 period. Our inventory turnover was 5.0 times in the 2000 period
compared to 4.6 times in the 1999 period. This increase is attributable to
higher inventory turnover at our lab communication devices operations.
We expect to continue to incur negative net cash flow from operations
until we begin receiving higher levels of revenues, primarily driven by
PROXYMED.COM, our healthcare web portal. Management is committed to the strategy
of investing funds in further marketing and development of our products and
services, specifically for PROXYMED.COM, which will integrate our existing
desktop products into a single internet-based solution. We may also pursue
additional acquisitions that are deemed to be in accordance with our business
strategy.
On May 8, 2000, we entered into an agreement with an investment bank
to serve as exclusive placement agent for us in connection with a proposed
private offering by that investment bank, on a best efforts basis, of up to
$20,000,000 of equity securities, plus an "overallotment option" for an
additional $10,000,000. In addition, at the option of both parties, the
investment bank may arrange for up to $6,000,000 of bridge financing for us in
the form of an 8% senior collateralized convertible promissory note and five
year warrants to purchase 500,000 shares of common stock for each $1,000,000 of
bridge financing. No assurance can be given that these financings will be
completed, or that, if completed, will be at the terms described herein.
14
<PAGE>
CAUTIONARY STATEMENT PURSUANT TO SAFE HARBOR PROVISIONS OF THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This document contains forward-looking statements that reflect the
Company's current expectations regarding future events including the Company's
ability to redeem its Preferred Stock. While these statements reflect the
Company's best current judgment, they are subject to risks and uncertainties.
Actual results may differ significantly from projected results due to a number
of factors, including, but not limited to ProxyMed's ability to abide by the
terms of the redemption and related agreements, assumptions, beliefs and
opinions relating to ProxyMed's growth strategy based upon ProxyMed's
interpretation and analysis of healthcare industry trends and management's
ability to successfully develop, market, sell and implement its e-commerce
solutions, clinical and financial e-transaction services and software
applications to physicians, pharmacies, laboratories, and payers. These factors
and other risk factors are more fully discussed in the Company's filings with
the Securities and Exchange Commission. ProxyMed expressly disclaims any intent
or obligation to update any forward-looking statements.
15
<PAGE>
PART II - OTHER INFORMATION
ITEM 5 - OTHER INFORMATION.
Subsequent to the quarter ended March 31, 2000, ProxyMed has filed the
following reports on Form 8-K:
- May 8, 2000 - Report on Redemption and Exchange Agreement
reached with ProxyMed's Series B Preferred stockholders.
- May 9, 2000 - Report on engagement of investment bank to
assist ProxyMed in a capital raising transaction and serve as
exclusive financial advisor.
ITEM 6 - EXHIBITS AND REPORTS ON FORM 8-K.
(a) Exhibits:
27 - Financial Data Schedule.
(b) Reports on Form 8-K:
No reports on Form 8-K were filed during the quarter ended
March 31, 2000.
16
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
PROXYMED, INC.
(Registrant)
May 15, 2000 /s/ BENNETT MARKS
-----------------
(Date) Bennett Marks
Executive Vice-President, Chief
Financial Officer and Principal
Accounting Officer
17
<PAGE>
EXHIBIT INDEX
EXHIBIT DESCRIPTION
- ------- -----------
27 Financial Data Schedule
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JAN-01-2000
<PERIOD-END> MAR-31-2000
<CASH> 7,914,054
<SECURITIES> 0
<RECEIVABLES> 4,551,632
<ALLOWANCES> (695,824)
<INVENTORY> 2,442,994
<CURRENT-ASSETS> 16,724,858
<PP&E> 7,383,187
<DEPRECIATION> (2,630,992)
<TOTAL-ASSETS> 39,797,945
<CURRENT-LIABILITIES> 8,708,314
<BONDS> 0
0
150
<COMMON> 18,299
<OTHER-SE> 30,544,155
<TOTAL-LIABILITY-AND-EQUITY> 39,797,945
<SALES> 3,390,602
<TOTAL-REVENUES> 7,644,950
<CGS> 2,339,490
<TOTAL-COSTS> 2,744,882
<OTHER-EXPENSES> 10,922,594
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> (92,231)
<INCOME-PRETAX> (5,929,295)
<INCOME-TAX> 0
<INCOME-CONTINUING> (5,929,295)
<DISCONTINUED> 207,203
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (5,722,092)
<EPS-BASIC> (0.32)
<EPS-DILUTED> (0.32)
</TABLE>
